Anavex Life Sciences (AVXL) Expected to Announce Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) is expected to be posting its Q4 2025 results before the market opens on Monday, December 22nd. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. During the same quarter in the previous year, the business earned ($0.14) earnings per share. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Performance

AVXL stock opened at $3.67 on Friday. The company has a market capitalization of $327.91 million, a price-to-earnings ratio of -6.80 and a beta of 1.15. The business’s 50 day moving average price is $5.88 and its two-hundred day moving average price is $8.42. Anavex Life Sciences has a fifty-two week low of $2.86 and a fifty-two week high of $14.44.

Analysts Set New Price Targets

AVXL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Anavex Life Sciences in a research report on Monday. HC Wainwright reaffirmed a “buy” rating on shares of Anavex Life Sciences in a report on Friday, November 28th. Jones Trading downgraded shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 24th. Wall Street Zen downgraded shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 23rd. Finally, D. Boral Capital restated a “buy” rating on shares of Anavex Life Sciences in a report on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Anavex Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $44.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its position in Anavex Life Sciences by 6.1% during the second quarter. Rhumbline Advisers now owns 128,370 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 7,377 shares during the last quarter. Legal & General Group Plc boosted its position in Anavex Life Sciences by 19.0% in the second quarter. Legal & General Group Plc now owns 86,972 shares of the biotechnology company’s stock worth $802,000 after purchasing an additional 13,886 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Anavex Life Sciences by 10.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock valued at $434,000 after purchasing an additional 4,869 shares during the period. Raymond James Financial Inc. increased its position in shares of Anavex Life Sciences by 29.2% during the 2nd quarter. Raymond James Financial Inc. now owns 22,130 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Anavex Life Sciences during the 3rd quarter valued at about $153,000. Institutional investors own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.